Researchers demonstrated the equivalence of the effect of delivering early palliative care via video versus in-person visits on quality of life in patients with advanced lung cancer.
Newly defined strategy will extend the frontier for research-driven excellence in cancer care across all patients and across all communities.
A study led by researchers at Mass General Brigham has found that an individualized cancer therapy tailored to the unique tumor profiles of patients with melanoma and lung cancer was well-tolerated and boosted immune activity.
The findings challenge the use of pack-year smoking history in determining lung cancer screening eligibility and support the use of smoking duration cutoffs instead.
Researchers report a new pathway underlying the anti-cancer mechanism of mIDH1 inhibitors, involving the process of “viral mimicry.”
Researchers comprehensively evaluated occurrence patterns of immune-related adverse events in cancer patients being treated with immune checkpoint inhibitors, from those affecting single organs to those involving two or more organs.
Clinical trial generates promising results for brigatinib as a treatment for the genetic condition, which is characterized by brain and nerve sheath tumors.
The findings could lead to new strategies to treat metastatic cancer and would be particularly impactful for patients with pancreatic cancer.
The discovery of a CDH1 gene mutation in the family led Gretchen Borzi on a journey of genetic testing and preventative surgery with a multidisciplinary team. Learn more.
Patients with advanced lung cancer who received stepped palliative care reported similar quality of life (QOL) scores as those who received monthly palliative care visits from the time of diagnosis.
An integral part of one of the world’s most distinguished academic medical centers, Mass General Cancer Center is among the leading cancer care providers in the United States.
